{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:27:21Z","timestamp":1773386841267,"version":"3.50.1"},"reference-count":14,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"3","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Hepatitis C virus (HCV) incidence rates are rising for patients with substance use and\/or SUDs. Guidelines provide monitoring recommendations to ensure remission after successful treatment. The study's objective was to identify gaps in follow-up for patients with documented substance use and\/or SUD through assessment of adherence to guideline-recommended HCV RNA lab 12 months post-treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients treated for HCV through the Veteran Health Indiana Hepatitis C Pharmacy Clinic were retrospectively evaluated. Subjects were categorized based on the provider assigned for follow-up care after 12-week sustained virologic response (SVR12) labs (primary care provider [PCP] or HCV provider). The primary outcome was HCV RNA obtained 11 to 13 months post-treatment. Secondary outcomes were HCV RNA detected post-treatment, substance use, engagement in substance use treatment, and engagement with social work.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Two hundred forty-one patients were included in the HCV provider cohort and 139 in the PCP cohort. Forty-one patients did not have a specified clinic for follow-up treatment, and 20 patients did not achieve SVR12. Sixty-one patients (28%) in the HCV provider cohort completed a 12-month HCV RNA within 11 to 13 months post-treatment vs 15 patients (11%) in the PCP cohort (P\u2009\u2264\u2009.01). One patient had HCV RNA detected post-treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>This study reveals inadequate HCV post-treatment follow-up for patients with substance use and\/or SUD. SUD is a chronic disease that requires continued monitoring to prevent complications. Further studies are needed to identify reinfection rates and improvements of care in this population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2022.06.181","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T15:15:23Z","timestamp":1654874123000},"page":"181-186","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of hepatitis C monitoring adherence after viral eradication in veterans with substance use to improve care and surveil reinfection"],"prefix":"10.9740","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3057-4331","authenticated-orcid":true,"given":"Miranda L.","family":"Stratton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9835-0305","authenticated-orcid":true,"given":"Elayne D.","family":"Ansara","sequence":"additional","affiliation":[{"name":"2 Clinical Pharmacy Practitioner \u2013 Mental Health, Veteran Health Indiana, Indianapolis, Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3986-8849","authenticated-orcid":true,"given":"Amanda P.","family":"Ifeachor","sequence":"additional","affiliation":[{"name":"3 Clinical Pharmacy Practitioner \u2013 Ambulatory Care (Gastrointestinal\/Hepatitis C Virus Clinics), Veteran Health Indiana, Indianapolis, Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4800-5671","authenticated-orcid":true,"given":"Kelly K.","family":"Houck","sequence":"additional","affiliation":[{"name":"4 Facility Pain Management, Opioid Safety, and Prescription Drug Monitoring Program (PMOP) Coordinator, Veteran Health Indiana, Indianapolis, Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-8123","authenticated-orcid":true,"given":"Suthat","family":"Liangpunsakul","sequence":"additional","affiliation":[{"name":"5 Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana and Associate Chief of Staff for Research service and Hepatologist, Gastroenterology Section, Medicine Service, Veteran Health Indiana, Indianapolis, Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2031-5646","authenticated-orcid":true,"given":"Katie J.","family":"Binger","sequence":"additional","affiliation":[{"name":"6 Clinical Pharmacy Practitioner \u2013 Mental Health, Veteran Health Indiana, Indianapolis, Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"2022061015145406100_i2168-9709-12-3-181-b01","unstructured":"Centers for Disease Control and Prevention [Internet].\n          2019 Viral hepatitis surveillance report [updated\n          2021\n          Jul;\n\t\t\t\t\tcited 2021 Dec 10].Available from: https:\/\/www.cdc.gov\/hepatitis\/statistics\/SurveillanceRpts.htm"},{"key":"2022061015145406100_i2168-9709-12-3-181-b02","doi-asserted-by":"crossref","unstructured":"Morgan\n              TR,\n            \n            \n              Ghany\n              MG,\n            \n            \n              Kim\n              H-Y,\n            \n            \n              Snow\n              KK,\n            \n            \n              Shiffman\n              ML,\n            \n            \n              De Santo\n              JL,\n            \n            et al.\n          \n          Outcome of sustained virological responders with histologically advanced chronic hepatitis C.\n\t\t\t\t\tHepatology.\n\t\t\t\t\t2010;\n\t\t\t\t\t52(3):\n\t\t\t\t\t833-\n\t\t\t\t\t44.\n\t\t\t\t\tDOI: 10.1002\/hep.23744. PubMed PMID: 20564351; PubMed Central PMCID: PMC2932862.","DOI":"10.1002\/hep.23744"},{"key":"2022061015145406100_i2168-9709-12-3-181-b03","doi-asserted-by":"crossref","unstructured":"Akiyama\n              MJ,\n            \n            \n              Lipsey\n              D,\n            \n            \n              Heo\n              M,\n            \n            \n              Agyemang\n              L,\n            \n            \n              Norton\n              BL,\n            \n            \n              Hidalgo\n              J,\n            \n            et al.\n          \n          Low hepatitis C reinfection following direct-acting antiviral therapy among people who inject drugs on opioid agonist therapy.\n\t\t\t\t\tClin Infect Dis.\n\t\t\t\t\t2019;\n\t\t\t\t\t70(12):\n\t\t\t\t\t2695-\n\t\t\t\t\t702.\n\t\t\t\t\tDOI: 10.1093\/cid\/ciz693. PubMed PMID: 31346609; PubMed Central PMCID: PMC7456350.","DOI":"10.1093\/cid\/ciz693"},{"key":"2022061015145406100_i2168-9709-12-3-181-b04","doi-asserted-by":"crossref","unstructured":"Jain\n              MK,\n            \n            \n              Thamer\n              M,\n            \n            \n              Therapondos\n              G,\n            \n            \n              Shiffman\n              ML,\n            \n            \n              Kshirsagar\n              O,\n            \n            \n              Clark\n              C,\n            \n            et al.\n          \n          Has access to hepatitis C virus therapy changed for patients with mental health or substance use disorders in the direct-acting-antiviral period?\n          Hepatology.\n\t\t\t\t\t2019;\n\t\t\t\t\t69(1):\n\t\t\t\t\t51-\n\t\t\t\t\t63.\n\t\t\t\t\tDOI: 10.1002\/hep.30171. PubMed PMID: 30019478.","DOI":"10.1002\/hep.30171"},{"key":"2022061015145406100_i2168-9709-12-3-181-b05","unstructured":"American Association for the Study of Liver Diseases [Internet]. HCV guidance: recommendations for testing, managing, and treating hepatitis C\n          [cited\n          2021\n          Jun 10]. Available from: https:\/\/www.hcvguidelines.org\/."},{"key":"2022061015145406100_i2168-9709-12-3-181-b06","doi-asserted-by":"crossref","unstructured":"AASLD\/IDSA HCV Guidance Panel.\n          Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.\n\t\t\t\t\tHepatology.\n\t\t\t\t\t2015;\n\t\t\t\t\t62(3):\n\t\t\t\t\t932-\n\t\t\t\t\t54.\n\t\t\t\t\tDOI: 10.1002\/hep.27950. PubMed PMID: 26111063.","DOI":"10.1002\/hep.27950"},{"key":"2022061015145406100_i2168-9709-12-3-181-b07","unstructured":"Department of Veterans Affairs [Internet].\n          Chronic hepatitis C virus (HCV) infection: treatment considerations\n          [cited\n          2021\n          Jul 6]. Available from: https:\/\/www.hepatitis.va.gov\/hcv\/treatment\/hcv-treatment-considerations.asp"},{"key":"2022061015145406100_i2168-9709-12-3-181-b08","doi-asserted-by":"crossref","unstructured":"Hajarizadeh\n              B,\n            \n            \n              Cunningham\n              EB,\n            \n            \n              Valerio\n              H,\n            \n            \n              Martinello\n              M,\n            \n            \n              Law\n              M,\n            \n            \n              Janjua\n              NZ,\n            \n            et al.\n          \n          Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis.\n\t\t\t\t\tJ Hepatology.\n\t\t\t\t\t2020;\n\t\t\t\t\t72(4):\n\t\t\t\t\t643-\n\t\t\t\t\t57.\n\t\t\t\t\tDOI: 10.1016\/j.jhep.2019.11.012. PubMed PMID: 31785345.","DOI":"10.1016\/j.jhep.2019.11.012"},{"key":"2022061015145406100_i2168-9709-12-3-181-b09","unstructured":"Krekulova\n              L,\n            \n            \n              Vavrincikova\n              L.\n            \n          \n          Experience with viral hepatitis C treatment among people who inject drugs and participate in a methadone substitution treatment program.\n\t\t\t\t\tEpidemiol Mikrobiol Imunol.\n\t\t\t\t\t2021;\n\t\t\t\t\t70(1):\n\t\t\t\t\t18-\n\t\t\t\t\t25.\n\t\t\t\t\tPubMed PMID: 33853334."},{"key":"2022061015145406100_i2168-9709-12-3-181-b10","doi-asserted-by":"crossref","unstructured":"Ifeachor\n              AP,\n            \n            \n              Houck\n              KK,\n            \n            \n              Schulte\n              S,\n            \n            \n              Ansara\n              E,\n            \n            \n              Johnson\n              AJ,\n            \n            \n              Carr\n              TA,\n            \n            et al.\n          \n          HCV eradication in veterans with underlying mental health disorders and substance use.\n\t\t\t\t\tJ Am Pharm Assoc (2003).\n\t\t\t\t\t2020;\n\t\t\t\t\t60(6):\n\t\t\t\t\t1037-\n\t\t\t\t\t43.e3.\n\t\t\t\t\tDOI: 10.1016\/j.japh.2020.08.028. PubMed PMID: 32948462.","DOI":"10.1016\/j.japh.2020.08.028"},{"key":"2022061015145406100_i2168-9709-12-3-181-b11","doi-asserted-by":"crossref","unstructured":"Harris\n              PA,\n            \n            \n              Taylor\n              R,\n            \n            \n              Thielke\n              R,\n            \n            \n              Payne\n              J,\n            \n            \n              Gonzalez\n              N,\n            \n            \n              Conde\n              JG.\n            \n          \n          Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support.\n\t\t\t\t\tJ Biomed Inform.\n\t\t\t\t\t2009;\n\t\t\t\t\t42(2):\n\t\t\t\t\t377-\n\t\t\t\t\t81.\n\t\t\t\t\tDOI: 10.1016\/j.jbi.2008.08.010. PubMed PMID: 18929686.","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2022061015145406100_i2168-9709-12-3-181-b12","doi-asserted-by":"crossref","unstructured":"Harris\n              PA,\n            \n            \n              Taylor\n              R,\n            \n            \n              Minor\n              BL,\n            \n            \n              Elliott\n              V,\n            \n            \n              Fernandez\n              M,\n            \n            \n              O'Neal\n              L,\n            \n            et al.\n          \n          The REDCap consortium: building an international community of software partners.\n\t\t\t\t\tJ Biomed Inform.\n\t\t\t\t\t2019;\n\t\t\t\t\t95:\n\t\t\t\t\t103208.\n\t\t\t\t\tDOI: 10.1016\/j.jbi.2019.103208. PubMed PMID: 31078660.","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2022061015145406100_i2168-9709-12-3-181-b13","doi-asserted-by":"crossref","unstructured":"Ho\n              SB,\n            \n            \n              Br\u00e4u\n              N,\n            \n            \n              Cheung\n              R,\n            \n            \n              Liu\n              L,\n            \n            \n              Sanchez\n              C,\n            \n            \n              Sklar\n              M,\n            \n            et al.\n          \n          Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse.\n\t\t\t\t\tClin Gastroenterol Hepatol.\n\t\t\t\t\t2015;\n\t\t\t\t\t13(11):\n\t\t\t\t\t2005-\n\t\t\t\t\t14.e1-3. DOI: 10.1016\/j.cgh.2015.02.022. PubMed PMID: 25724704.","DOI":"10.1016\/j.cgh.2015.02.022"},{"key":"2022061015145406100_i2168-9709-12-3-181-b14","unstructured":"Belani\n              H,\n            \n            \n              Chorba\n              T,\n            \n            \n              Fletcher\n              F,\n            \n            \n              Hennessey\n              K,\n            \n            \n              Kroeger\n              K,\n            \n            \n              Lansky\n              A,\n            \n            et al.\n          \n          Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. MMWR Recomm Rep.\n          2012;\n\t\t\t\t\t61(RR-5):1-40.PubMed PMID: 23135062."}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/12\/3\/181\/3071095\/i2168-9709-12-3-181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/12\/3\/181\/3071095\/i2168-9709-12-3-181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:23:49Z","timestamp":1731687829000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/12\/3\/article-p181.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6,10]]},"published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2022.06.181","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}